{"name":"Sciwind Biosciences USA Co., Ltd.","slug":"sciwind-biosciences-usa-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixAJBVV95cUxOTWRKUFFxSkZqdnVqMGlXaEVwaWtLV0dJc21RU2tqeGZpSzhhbEplcWFNUG8zVlk4OE9UVW56VmY0NmJkYjJTTTE0M3oxNlhteE1pNk1IQXhzZzVmTTZYNkVFR2tXMmlDdl84c1c5RHBSQU4wTDFhNzlCVDY5SldIcTBreHg0NnlRR0E0Q0hNM2xMRU43bXMwS0lkbGRKSzhHY2pWVkw2T29zd2w5TEItSW1uQjE5ejVOcmdZNWRQOTZfeFZyUEZucG9jZlZUMk9DMkhacVVPVngyU19ia04tUV9KZTZjM2duUldRN1Yzb2NraTB3VW5mbm9odEpJSEZxS2NvOWlZLThzaTRaWF9uZE9IRmVXd0d2YXVmRUhIOEtIaVItOVJzSGF6M0hDY3dENVhDODQzMzZ6U1BkWWlOdDM5Q2U?oc=5","date":"2026-04-08","type":"pipeline","source":"Barchart.com","summary":"Diabetes Market: Rapid Increment Driven by Innovation by 2032 – DelveInsight | Eli Lilly and Company, Regor Pharma AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova - Barcha","headline":"Diabetes Market: Rapid Increment Driven by Innovation by 2032 – DelveInsight | Eli Lilly and Company, Regor Pharma Astra","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-24","type":"deal","source":"The Economic Times","summary":"Pfizer in diabetes drug deal with Sciwind Biosciences - The Economic Times","headline":"Pfizer in diabetes drug deal with Sciwind Biosciences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNdHdQS2h6OS1wMUJjTFU4aHBEdkdSRW9RSTdkUXZhaG9KcnNiOFloRlhOYVItTVE0dHgwZ2dnY2lDSEppYW9NY2swUjRzajdpeWtBSXBHWEt1N3VMWHNaUDZxTHBiYWtmSjFzWDUzbzFNaGZUcDBDRXdPc0hPOUhuSUtzWkc2bnpnbG1oaG44T2J5NjNjbjh3b01YUGhKaGxOUXFweE5XU3hlX3RmRnlnRGRuX016UTZGbGJ0TTBTdw?oc=5","date":"2026-02-23","type":"deal","source":"Reuters","summary":"Pfizer in diabetes drug deal with Sciwind Biosciences - Reuters","headline":"Pfizer in diabetes drug deal with Sciwind Biosciences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxQaTNKT0tLYW5TQXNmZGcxSHppaUI4UlVWT1FOMW5pbmI4LVpHdEwzQjNBVmhCSzNsOExzQTYyWG9xQkJqUGVqZkxkMWlrRDUza1ptZG9Mc190RlUwSmx3OTRpZmtnUVZNT2xxcWNKR0YzUjRHOXVJajlRUHlGMUJRczh3bVJvVnY1WmZWXzZfNkNWMjluWWo4M0NXRXlueW40ZERwNWV6bi15b0lYWEtISDhabkRFTXFjdTdSVkU4SHM1VTNJM3FwempYd3ROaFc1LTlHLW9LWWFpckdSQ0c1Z2xyOS1QNDREc1Y2OWtRYkFtQWNOUGFCMg?oc=5","date":"2026-02-03","type":"pipeline","source":"prnewswire.com","summary":"Insulin Resistance Market Expected to Witness Strong Growth During the Forecast Period (2026-2036) | DelveInsight - prnewswire.com","headline":"Insulin Resistance Market Expected to Witness Strong Growth During the Forecast Period (2026-2036) | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQR2lKd1FyZTltbTVmcXNOMklnUWNNcXRzeGk3THF6TE90N250aUp1dFRPV1Myb05LMVhINUp5QktFbXBaRFQxc2hiQzJIcmtCNUYteGpscVhBVE5GR1AtUlFKd0VIb0xoX2ZOR2F3LTFrNldSYk1fc3VmNG9RZWwyQURnZHljdGw5U1d2T2liQXc2UVhGNjA3bGZ5cG4tcTdRRVp5QUZGSjlaUkFxWmFGMXZDanRPMnFUT3N3WQ?oc=5","date":"2026-01-30","type":"regulatory","source":"Reuters","summary":"Sciwind Biosciences diabetes drug approved in China - Reuters","headline":"Sciwind Biosciences diabetes drug approved in China","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMixAJBVV95cUxPVEdFQnVwd0NPdlBlZlVUa2p5M0RuRnJlN1l1dHhNMFdicmZoRTZtTWVNeHRZeHJmZnRyanNHT2hQYy1TQWFZT2wzVXdncjF0NWMyNGNYN3hzeVozTGx3aWh4eW9nVGc4RVI0R2o3bE5nVWR3NGlaejNNTkl2dzl3NVRnQ3J1YWFYVXpZYzFrMGgtakdLTUgtUUo5UFNPdE14ZjJwby16VTJoVXlHRDFFVnJuaGJLWUlvOGszbTdFOTZGemhkUjIyaG44bTk2bE5hV001YU9Sa096RWFxRENybTlSX0dVc3VBanVONTl6Y2VqVTMxQ3M0eXByQUxmak5NRV9JZXF5aWkxNlhaYW9tRC01Y0JZcktubGRSdEJlSDEwOUxOQ3RtWkJhOVI0YTM0ZFJxNEx1UHMxV0p4VGRfNGlfNnE?oc=5","date":"2025-09-23","type":"pipeline","source":"prnewswire.com","summary":"SGLT2 Inhibitors Market to Expand by 2034 as Companies Leverage Emerging Opportunities in Indications Such as Heart Failure, MASH, Obesity, PCOS, and Others | DelveInsight - prnewswire.com","headline":"SGLT2 Inhibitors Market to Expand by 2034 as Companies Leverage Emerging Opportunities in Indications Such as Heart Fail","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAJBVV95cUxOeHliYlFudThqcnhPN2I0VnNFT1MtbDNFRHl6X3VDTUMxZVgyV3ZORG1UdlNVYkRqd2ZNRVhDTjFzWWkwUzRIZlltSUtUTVhRRTdPRUFsY2l5N1pESkgwQVQ4dGVYZXpmRlFvNjRRd3BJdXg5ekt4ZkgzRmktNVJ6aU0zMURfdk9iZDdkV1NTR0tQd1dIeGE0RDM2dzB2M1NKSmVaSkM4U2NjVmZvcmZITS1qUXAtdi0zcnpZSHZfU0ZMZnBiS09Jai1MeDAxcUF5WElEcnRKMjR3a0lOQ1pVQ2xNS29EbVZPSGFTazJXWmtlWnVfS09QdmhCMktRRjV6?oc=5","date":"2025-09-05","type":"pipeline","source":"prnewswire.com","summary":"GLP-1 Agonists Market to Show Impressive Growth at a CAGR of 10.8% During the Forecast Period (2025-2034) | DelveInsight - prnewswire.com","headline":"GLP-1 Agonists Market to Show Impressive Growth at a CAGR of 10.8% During the Forecast Period (2025-2034) | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxONzhBVTJSZ2NoRGVkSDdJS1NtRmhCbDZDQUFRQ0RXbmdIeF9QVXNFY3BJUHJ3VXJwei0xVU11VVJXZDVGOEJFbDZqN1JXNmlObEVsVzFIOFQtTHE3bzV2V2I3emtCYS1aQXp5RFk5OE85LUU0Z1JtSzlQMjhfMkhFRU1ya21rNy1CSzdXMnR0M2c4WV9NcFZRTlY1NW1KNTdIMDFKSWZqYklQV0FQLW9IaFhIdk96dEliSE1Ub01jakFJLTBFQ0daOHpsaE4?oc=5","date":"2025-07-25","type":"deal","source":"Reuters","summary":"Exclusive: China's Sciwind is in talks to license weight-loss drug in US, CEO says - Reuters","headline":"Exclusive: China's Sciwind is in talks to license weight-loss drug in US, CEO says","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxPTVBROS02cE8tTzQteXNjWEFSRURwdDVxUXZ6TDlqaE12YXB4UndwV3FCdl9Mc25UeUd6aFdWdThwSXBfYW1EUEVMa1Fsa3RUWGlLNnZYX2xPdDRqVnZ4dVpwa0dXSVE5aHVKVm93aWVXRDlVWWZ4NnBmOEhkTV9haFJXaEZ4R3ZpQmZ5R0w4WkFPQjF0dG44aFcyQ1pIS0psWkxRVkluaEJzTG1fbGI0V0JqMjJjNWFMbnp2bi1mc3h5ZURIbmNfWVI3UnBJTHN3eDZzU0xISUxpVlRWcnFqOC1GVGo5N0NYRlN0aFpab2pub3ZvYVRPZjRPZzM?oc=5","date":"2025-04-07","type":"regulatory","source":"Barchart.com","summary":"Diabetes Pipeline Insights, Clinical Trials Report 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - Barchart.com","headline":"Diabetes Pipeline Insights, Clinical Trials Report 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, a","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQbjd4SWJyWFBZTy1OM0FjN2dKS2ltN0R0V0F1SF9rZDItbE1JblpjX2VEQXhHMWhrcjZLX0Rpa0dSNmI5b2I4T1hTMFdwcHVmY2hfU1AwQXIzMXZoQ04xRVBONnFYM0FyNURNR2hqaV9tWHp5ZXNSZjBjN1psNkdxY1hhVnAtR1pTSHY5ZWo2YzFlQQ?oc=5","date":"2025-01-10","type":"earnings","source":"The Pharma Letter","summary":"Sciwind’s Verdiva Bio deal earnings could top $2.4 billion - The Pharma Letter","headline":"Sciwind’s Verdiva Bio deal earnings could top $2.4 billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswJBVV95cUxPTm1iOVZkUkcwdDV3cF90OEpGZ3VLbGdJQ0ZaWDNFa3BlMUF0ZS1CUTB5TWV2eHlFbkh1cXl6RjJFaHZlR1RVLVNTd1FDM19RRExiaEJIYndWWEk5ekp5aUlXNXRNbXFIYkFFUDlhOGdSRlRNZDlSN2IwekIyZ0ZES1FfdTVFY0JacTY3Z3Q3WE9kbUtERl9kVlFIY3Yzd2pqN19Wc1VHeHhNNU9ZZF9wa29qeDNDZC1wVFRFOGVSQTlRdTNNem5XRnJWR1lLNkRJOXBIZ2lSd0E0WU44dXhaaVo1dlkwdjR2Q3F6bUZkM3JkamtCTVYyMEhDQVRZLXBqd0VHWGctQmtLb2tyaC1mSk9RcEZVZ2RtUzdQZDRVcW9oLUV1VHMwbnVvczVlUUFTX3dz?oc=5","date":"2024-07-23","type":"trial","source":"GlobeNewswire","summary":"GLP Agonist Clinical Trial Pipeline Appears Robust With 20+ - GlobeNewswire","headline":"GLP Agonist Clinical Trial Pipeline Appears Robust With 20+","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}